Assessment	B:C0220825
of	O
Residual	O
Disease	I:C0543478
With	O
Molecular	O
Breast	I:C2985547
Imaging	I:C2985547
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	I:C0600558
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
Residual	B:C0543478
Disease	I:C0543478
With	O
Molecular	O
Breast	I:C2985547
Imaging	I:C2985547
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	I:C0600558
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
Residual	O
Disease	I:C0543478
With	O
Molecular	B:C2985547
Breast	I:C2985547
Imaging	I:C2985547
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	I:C0600558
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
Residual	O
Disease	I:C0543478
With	O
Molecular	O
Breast	I:C2985547
Imaging	I:C2985547
in	O
Patients	O
Undergoing	O
Neoadjuvant	B:C0600558
Therapy	I:C0600558
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
Residual	O
Disease	I:C0543478
With	O
Molecular	O
Breast	I:C2985547
Imaging	I:C2985547
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	I:C0600558
:	O
Association	O
With	O
Molecular	O
Subtypes	B:C0449560
.	O

Assessment	B:C0220825
of	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
for	O
breast	O
cancer	I:C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	O
.	O

Assessment	O
of	O
residual	B:C0543478
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
for	O
breast	O
cancer	I:C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	O
.	O

Assessment	O
of	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	B:C0600558
therapy	I:C0600558
for	O
breast	O
cancer	I:C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	O
.	O

Assessment	O
of	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
for	O
breast	B:C0006142
cancer	I:C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	O
.	O

Assessment	O
of	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
for	O
breast	O
cancer	I:C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B:C0006141
imaging	O
.	O

Assessment	O
of	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
for	O
breast	O
cancer	I:C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	B:C0011923
.	O

This	O
study	B:C2603343
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	B:C0220825
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	B:C1258740
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	B:C0543478
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	B:C0600558
therapy	I:C0600558
in	O
patients	O
with	O
breast	O
cancer	I:C0006142
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
(	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	I:C1258740
telluride	I:C1258740
detectors	O
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
therapy	I:C0600558
in	O
patients	O
with	O
breast	B:C0006142
cancer	I:C0006142
.	O

Clinical	B:C1516606
data	I:C1516606
,	O
imaging	O
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	O
cancer	I:C0006142
undergoing	O
neoadjuvant	O
therapy	I:C0600558
were	O
recorded	O
.	O

Clinical	O
data	I:C1516606
,	O
imaging	B:C0011923
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	O
cancer	I:C0006142
undergoing	O
neoadjuvant	O
therapy	I:C0600558
were	O
recorded	O
.	O

Clinical	O
data	I:C1516606
,	O
imaging	O
,	O
surgical	O
,	O
and	O
pathological	O
findings	B:C0243095
of	O
51	O
women	O
with	O
breast	O
cancer	I:C0006142
undergoing	O
neoadjuvant	O
therapy	I:C0600558
were	O
recorded	O
.	O

Clinical	O
data	I:C1516606
,	O
imaging	O
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	B:C0043210
with	O
breast	O
cancer	I:C0006142
undergoing	O
neoadjuvant	O
therapy	I:C0600558
were	O
recorded	O
.	O

Clinical	O
data	I:C1516606
,	O
imaging	O
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	B:C0006142
cancer	I:C0006142
undergoing	O
neoadjuvant	O
therapy	I:C0600558
were	O
recorded	O
.	O

Clinical	O
data	I:C1516606
,	O
imaging	O
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	O
cancer	I:C0006142
undergoing	O
neoadjuvant	B:C0600558
therapy	I:C0600558
were	O
recorded	O
.	O

molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
findings	O
were	O
correlated	O
with	O
surgical	O
pathology	I:C1710255
results	I:C1710255
.	O

molecular	O
breast	I:C2985547
imaging	I:C2985547
findings	B:C0243095
were	O
correlated	O
with	O
surgical	O
pathology	I:C1710255
results	I:C1710255
.	O

molecular	O
breast	I:C2985547
imaging	I:C2985547
findings	O
were	O
correlated	O
with	O
surgical	B:C1710255
pathology	I:C1710255
results	I:C1710255
.	O

Accuracy	O
of	O
molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
in	O
predicting	O
complete	O
pathological	I:C4050242
response	I:C4050242
and	O
size	O
of	O
residual	O
disease	I:C0543478
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

Accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
predicting	O
complete	B:C4050242
pathological	I:C4050242
response	I:C4050242
and	O
size	O
of	O
residual	O
disease	I:C0543478
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

Accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
predicting	O
complete	O
pathological	I:C4050242
response	I:C4050242
and	O
size	B:C0456389
of	O
residual	O
disease	I:C0543478
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

Accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
predicting	O
complete	O
pathological	I:C4050242
response	I:C4050242
and	O
size	O
of	O
residual	B:C0543478
disease	I:C0543478
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

Accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
predicting	O
complete	O
pathological	I:C4050242
response	I:C4050242
and	O
size	O
of	O
residual	O
disease	I:C0543478
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	B:C0449560
.	O

The	O
size	B:C0456389
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O

The	O
size	O
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	B:C3539878
negative	I:C3539878
and	O
HER2	O
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
subtypes	O
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	O
negative	I:C3539878
and	O
HER2	B:C2348909
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
subtypes	O
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	O
negative	I:C3539878
and	O
HER2	O
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
subtypes	B:C0449560
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O

Sixteen	O
patients	O
(	O
31	O
%	O
)	O
had	O
complete	B:C4050242
pathological	I:C4050242
response	I:C4050242
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
for	O
detecting	O
residual	O
disease	I:C0543478
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66-93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
-	O
88	O
)	O
,	O
respectively	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
for	O
detecting	O
residual	B:C0543478
disease	I:C0543478
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66-93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
-	O
88	O
)	O
,	O
respectively	O
.	O

For	O
triple	B:C3539878
negative	I:C3539878
or	O
HER2	O
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62-98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-93	O
)	O
,	O
respectively	O
.	O

For	O
triple	O
negative	I:C3539878
or	O
HER2	B:C2348909
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62-98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-93	O
)	O
,	O
respectively	O
.	O

The	O
accuracy	O
of	O
molecular	B:C2985547
breast	I:C2985547
imaging	I:C2985547
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
treatment	I:C0600558
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

The	O
accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
assessing	O
residual	B:C0543478
disease	I:C0543478
after	O
neoadjuvant	O
treatment	I:C0600558
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

The	O
accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	B:C0600558
treatment	I:C0600558
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

The	O
accuracy	O
of	O
molecular	O
breast	I:C2985547
imaging	I:C2985547
in	O
assessing	O
residual	O
disease	I:C0543478
after	O
neoadjuvant	O
treatment	I:C0600558
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	B:C0449560
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	B:C3539878
negative	I:C3539878
and	O
HER2	O
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
subtypes	O
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	O
negative	I:C3539878
and	O
HER2	B:C2348909
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
subtypes	O
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	O
negative	I:C3539878
and	O
HER2	O
/	I:C2348909
neu	I:C2348909
positive	I:C2348909
subtypes	B:C0449560
.	O

